BETTER MEDICARE ALLIANCE STATEMENT ON AFFORDABLE MEDICARE DRUG PRICING
Washington, D.C. - Better Medicare Alliance (BMA) President and CEO Allyson Y. Schwartz released the following statement in response to U.S. Senate Finance Committee Hearing on prescription drug prices:
“As a coalition of over 100 organizations and nearly 400,000 senior advocates dedicated to strengthening affordable, high-quality care under Medicare Advantage, BMA is encouraged by efforts of Senators Orrin Hatch and Ron Wyden to thoughtfully consider solutions to the problem of high prescription drug costs.
“Even with high satisfaction among beneficiaries in Medicare Advantage, concern about high prescription drug prices remain. Access and affordability is important to all beneficiaries, particularly those requiring life-saving drugs and medications necessary to support disease management.
“As an integrated system of care, Medicare Advantage offers affordable coverage to 20 million enrollees many of whom live with multiple chronic conditions and depend on daily prescription drugs. Nearly half of Medicare Advantage beneficiaries have annual incomes of less than $20,000 and find the cost of prescription drugs a burden. For these reasons, BMA supports bipartisan legislation such as the CREATES ACT which would help increase access to affordable prescription drugs.
“We look forward to examining future proposals from the Senate Finance Committee and the opportunity to weigh-in on behalf of our ally organizations and the 20 million Medicare Advantage beneficiaries who depend on prescription drugs at an affordable cost.”